merck & co. inc. (MRK:New York)
Transactions by MERCK & CO. INC. (MRK) in the last 6 months
The Board of Directors of Merck & Co., Inc. (NYSE:MRK) authorized a share repurchase program on May 1, 2013. Under the program, the company will repurchase up to $15 billion worth of its shares. The repurchases will be made in the open-market, block transactions on or off an exchange, or in privately negotiated transactions. The shares will be repurchased for its treasury. The company expects to finance approximately $7.5 billion repurchases through a combination of ...
Cerecor, Inc. acquired rights to NR2B receptor antagonist from Merck & Co. Inc. (NYSE:MRK) on April 19, 2013. The consideration for the transaction includes milestone payments and royalties consistent with clinical stage licenses in neuroscience. Michelle Avery of MacDougall Biomedical Communications acted as public relations advisor in the transaction.
Hawaii Biotech, Inc. acquired patent family to West Nile virus vaccine technology from Merck & Co. Inc. (NYSE:MRK) on April 11, 2013.
Cerecor, Inc. acquired worldwide rights to COMT Inhibitors from Merck & Co. Inc. (NYSE:MRK) on March 20, 2013.
|Bayer AG||€84.28 EUR||-0.30|
|GlaxoSmithKline PLC||1,713 GBp||+5.00|
|L'Oreal SA||€135.00 EUR||-1.65|
|Roche Holding AG||SFr.247.00 CHF||+1.00|
|View Industry Companies|